Lilly sues four compounders over copies of weight-loss drugs Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge ...

Greg Page has revealed his brand new role in show business. The former star of the Wiggles, who hung up his Yellow Wiggle skivvy back in 2013, is back on the stage. The 53-year-old is ...

Learn More » Patients self-administer, through injection, the Novo Nordisk and Lilly drugs, and they do this on a weekly basis. The pharma giants aren't stopping there, though. The next big ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best American dividend stocks. Dividend-paying stocks have long benefited investors by ...

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.

Lilly soars on first data for oral obesity candidate Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Eli Lilly & Co reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of Novo Nordisk. The investment firm slashed its price target on NVO ...

Eli Lilly jumps as oral GLP-1 drug succeeds in Phase 3 trial Eli Lilly (LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist orforglipron ...